Skip to Content

Docefrez Approval History

FDA Approved: Yes (First approved May 3, 2011)
Brand name: Docefrez
Generic name: docetaxel
Dosage form: for Injection
Company: Sun Pharmaceutical Industries Inc.
Treatment for: Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer

Marketing Status: Discontinued

Docefrez (docetaxel) is a microtubule inhibitor indicated for the treatment of metastatic breast cancer, metastatic non-small cell lung cancer and hormone refractory metastatic prostate cancer.

Development History and FDA Approval Process for Docefrez

DateArticle
May  4, 2011Approval Sun Pharma Announces US FDA Approval for Docefrez (docetaxel) for Injection

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide